MedDataX Logo

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

NCT ID: NCT06311383

Last Updated: 2025-12-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2610 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-09

Study Completion Date

2025-02-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a non-interventional observational study conducted in Germany to evaluate the real-world effectiveness, tolerability, safety, and quality of life in patients with locally advanced/metastatic HR+/HER2- breast cancer treated with one of the following 1st line treatments: Ribociclib + AI/FUL, or endocrine monotherapy, or chemotherapy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This non-interventional study collects data from clinical practice capturing on effectiveness, safety and tolerability, duration of therapy, and quality of life of ribociclib in combination with an aromatase inhibitor/fulvestrant in daily routine and in line with the respective current German summary of product characteristics. In order to put these results into perspective, data is also collected on patients treated with endocrine therapy or chemotherapy for first line locally advanced or metastatic breast cancer. To gain insight into algorithms and outcome of sequential therapy, up to three lines of treatment are documented within this study. The information gathered and evaluated in this NIS is helping to answer open questions for the treatment of locally advanced/metastatic breast cancer and provides first insights into the treatment reality with ribociclib in this setting. This includes, but is not limited to, the questions on baseline demographics leading to a specific treatment decision, as well as efficacy and clinical routine related to treatment sequencing. In addition, data on the mutation status (including PIK3CA and BRCA1/2) is collected at different time points to generate insights into the clinical routine of mutation testing and to understand its impact on therapy sequencing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Breast Cancer NIS Ribociclib Metastatic Breast Cancer HR+ HER2- Real World Evidence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

First-line Ribociclib + endocrine therapy

Ribociclib + letrozole, or Ribociclib + anastrozole, or Ribociclib + exemestane, or Ribociclib + fulvestrant

First-line Ribociclib + endocrine therapy

Intervention Type DRUG

Ribociclib + letrozole, or Ribociclib + anastrazole, or Ribociclib + exemestane, or Ribociclib + fulvestrant

First-line endocrine therapy

As of physicians choice

First-line endocrine therapy

Intervention Type DRUG

As of physicians choice

First-line chemotherapy

As of physicians choice

First-line chemtherapy

Intervention Type DRUG

As of physicians choice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

First-line Ribociclib + endocrine therapy

Ribociclib + letrozole, or Ribociclib + anastrazole, or Ribociclib + exemestane, or Ribociclib + fulvestrant

Intervention Type DRUG

First-line endocrine therapy

As of physicians choice

Intervention Type DRUG

First-line chemtherapy

As of physicians choice

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a histological diagnosis of locally advanced/metastatic HR+/HER2- breast cancer. Histological diagnosis does not necessarily origin from metastasis, but must reflect the most recent disease status
* No prior systemic treatment for locally advanced/metastatic disease in the palliative setting
* The treating physician has made the decision to treat the patient
* with ribociclib in combination with an aromatase inhibitor or fulvestrant as initial treatment in first line, or
* endocrine therapy as initial treatment in first line (e.g. letrozole, anastrozole, fulvestrant), or
* chemotherapy as initial treatment in first line (e.g. taxanes, capecitabine, with or without bevacizumab)
* Written informed consent of the patient
* Patient who initiated treatment for first line no longer than 4 weeks (28 days) prior to written informed consent for this study
* Planned treatment is in line with the respective current German SmPC ("Summary of product characteristics")
* Patient is ≥18 years

Exclusion Criteria

* Patients unable to provide written informed consent
* Contra-indication according to the respective current German SmPC ("Summary of product characteristics"), as judged by the treating physician
* The patient is currently under active treatment in an investigational study
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novartis Investigative Site

Baden-Baden, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Freudenstadt, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Heidenheim, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Karlsruhe, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Mannheim, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Mannheim, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Mutlangen, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Nürtingen, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Ostfildern, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Reutlingen, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Rottweil, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Schwaebisch, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Sigmaringen, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Winnenden, Baden-Wurttemberg, Germany

Site Status

Novartis Investigative Site

Altötting, Bavaria, Germany

Site Status

Novartis Investigative Site

Amberg, Bavaria, Germany

Site Status

Novartis Investigative Site

Ansbach, Bavaria, Germany

Site Status

Novartis Investigative Site

Aschaffenburg, Bavaria, Germany

Site Status

Novartis Investigative Site

Augsburg, Bavaria, Germany

Site Status

Novartis Investigative Site

Bamberg, Bavaria, Germany

Site Status

Novartis Investigative Site

Bayreuth, Bavaria, Germany

Site Status

Novartis Investigative Site

Donauwörth, Bavaria, Germany

Site Status

Novartis Investigative Site

Ebersberg, Bavaria, Germany

Site Status

Novartis Investigative Site

Eggenfelden, Bavaria, Germany

Site Status

Novartis Investigative Site

Kempten (Allgäu), Bavaria, Germany

Site Status

Novartis Investigative Site

Kronach, Bavaria, Germany

Site Status

Novartis Investigative Site

Krumbach, Bavaria, Germany

Site Status

Novartis Investigative Site

Landshut, Bavaria, Germany

Site Status

Novartis Investigative Site

Munich, Bavaria, Germany

Site Status

Novartis Investigative Site

Munich, Bavaria, Germany

Site Status

Novartis Investigative Site

Munich, Bavaria, Germany

Site Status

Novartis Investigative Site

Nuremberg, Bavaria, Germany

Site Status

Novartis Investigative Site

Regensburg, Bavaria, Germany

Site Status

Novartis Investigative Site

Straubing, Bavaria, Germany

Site Status

Novartis Investigative Site

Würzburg, Bavaria, Germany

Site Status

Novartis Investigative Site

Würzburg, Bavaria, Germany

Site Status

Novartis Investigative Site

Mannheim, Beden Wuerttenberg, Germany

Site Status

Novartis Investigative Site

Brandenburg, Brandenburg, Germany

Site Status

Novartis Investigative Site

Cottbus, Brandenburg, Germany

Site Status

Novartis Investigative Site

Doberlug-Kirchhain, Brandenburg, Germany

Site Status

Novartis Investigative Site

Fürstenwalde, Brandenburg, Germany

Site Status

Novartis Investigative Site

Ludwigsfelde, Brandenburg, Germany

Site Status

Novartis Investigative Site

Neu-Brandenburg, Brandenburg, Germany

Site Status

Novartis Investigative Site

Spremberg, Brandenburg, Germany

Site Status

Novartis Investigative Site

Bremen, City state Bremen, Germany

Site Status

Novartis Investigative Site

Bremen, City state Bremen, Germany

Site Status

Novartis Investigative Site

Bremerhaven, City state Bremen, Germany

Site Status

Novartis Investigative Site

Schwerte, Germany, Germany

Site Status

Novartis Investigative Site

Wiesbaden, Germany, Germany

Site Status

Novartis Investigative Site

Hamburg, Hamburg, Germany

Site Status

Novartis Investigative Site

Hamburg, Hamburg, Germany

Site Status

Novartis Investigative Site

Hamburg, Hamburg, Germany

Site Status

Novartis Investigative Site

Bad Homburg, Hesse, Germany

Site Status

Novartis Investigative Site

Bad Nauheim, Hesse, Germany

Site Status

Novartis Investigative Site

Darmstadt, Hesse, Germany

Site Status

Novartis Investigative Site

Erbach im Odenwald, Hesse, Germany

Site Status

Novartis Investigative Site

Frankfurt am Main, Hesse, Germany

Site Status

Novartis Investigative Site

Frankfurt am Main, Hesse, Germany

Site Status

Novartis Investigative Site

Frankfurt am Main, Hesse, Germany

Site Status

Novartis Investigative Site

Langen, Hesse, Germany

Site Status

Novartis Investigative Site

Lich, Hesse, Germany

Site Status

Novartis Investigative Site

Marburg, Hesse, Germany

Site Status

Novartis Investigative Site

Braunschweig, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Buchholz, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Damme, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Georgsmarienhütte, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Hamelin, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Hanover, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Hildesheim, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Ilsede, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Lingen Ems, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Osnabrück, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Quedlinburg, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Twistringen, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Westerstede, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Wolfenbüttel, Lower Saxony, Germany

Site Status

Novartis Investigative Site

Rostock, Mecklenburg-Vorpommern, Germany

Site Status

Novartis Investigative Site

Schwerin, Mecklenburg-Vorpommern, Germany

Site Status

Novartis Investigative Site

Stralsund, Mecklenburg-Vorpommern, Germany

Site Status

Novartis Investigative Site

Arnsberg, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Bergisch Gladbach, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Bielefeld, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Bielefeld, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Bochum, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Bonn, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Bonn, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Cologne, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Cologne, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Dortmund, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Dortmund, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Düsseldorf, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Düsseldorf, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Gelsenkirchen, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Hagen, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Herdecke, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Herne, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Hilden, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Krefeld, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Lemgo, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Mönchengladbach, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Olpe, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Paderborn, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Remscheid, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Siegen, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Troisdorf, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Velbert, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Wesel, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Wesel, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Witten, North Rhine-Westphalia, Germany

Site Status

Novartis Investigative Site

Remscheid Innen, Northrhine Westfalia, Germany

Site Status

Novartis Investigative Site

Mayen, Rhineland-Palatinate, Germany

Site Status

Novartis Investigative Site

Neustadt, Rhineland-Palatinate, Germany

Site Status

Novartis Investigative Site

Simmern, Rhineland-Palatinate, Germany

Site Status

Novartis Investigative Site

Lebach, Saarland, Germany

Site Status

Novartis Investigative Site

Dresden, Saxony, Germany

Site Status

Novartis Investigative Site

Dresden, Saxony, Germany

Site Status

Novartis Investigative Site

Leipzig, Saxony, Germany

Site Status

Novartis Investigative Site

Leipzig, Saxony, Germany

Site Status

Novartis Investigative Site

Lohsa-Weisskollm, Saxony, Germany

Site Status

Novartis Investigative Site

Pirna, Saxony, Germany

Site Status

Novartis Investigative Site

Rodewisch, Saxony, Germany

Site Status

Novartis Investigative Site

Scheibenberg, Saxony, Germany

Site Status

Novartis Investigative Site

Schkeuditz, Saxony, Germany

Site Status

Novartis Investigative Site

Zittau, Saxony, Germany

Site Status

Novartis Investigative Site

Zxickau, Saxony, Germany

Site Status

Novartis Investigative Site

Halle, Saxony-Anhalt, Germany

Site Status

Novartis Investigative Site

Magdeburg, Saxony-Anhalt, Germany

Site Status

Novartis Investigative Site

Magdeburg, Saxony-Anhalt, Germany

Site Status

Novartis Investigative Site

Flensburg, Schleswig-Holstein, Germany

Site Status

Novartis Investigative Site

Lübeck, Schleswig-Holstein, Germany

Site Status

Novartis Investigative Site

Berlin, State of Berlin, Germany

Site Status

Novartis Investigative Site

Berlin, State of Berlin, Germany

Site Status

Novartis Investigative Site

Berlin, State of Berlin, Germany

Site Status

Novartis Investigative Site

Berlin, State of Berlin, Germany

Site Status

Novartis Investigative Site

Apolda, Thuringia, Germany

Site Status

Novartis Investigative Site

Eisenach, Thuringia, Germany

Site Status

Novartis Investigative Site

Erfurt, Thuringia, Germany

Site Status

Novartis Investigative Site

Jena, Thuringia, Germany

Site Status

Novartis Investigative Site

Meiningen, Thuringia, Germany

Site Status

Novartis Investigative Site

Mühlhausen, Thuringia, Germany

Site Status

Novartis Investigative Site

Suhl, Thuringia, Germany

Site Status

Novartis Investigative Site

Altötting, , Germany

Site Status

Novartis Investigative Site

Augsburg, , Germany

Site Status

Novartis Investigative Site

Augsburg, , Germany

Site Status

Novartis Investigative Site

Bad Liebenwerda, , Germany

Site Status

Novartis Investigative Site

Bamberg, , Germany

Site Status

Novartis Investigative Site

Bayreuth, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Berlin, , Germany

Site Status

Novartis Investigative Site

Bochum, , Germany

Site Status

Novartis Investigative Site

Bonn, , Germany

Site Status

Novartis Investigative Site

Bonn, , Germany

Site Status

Novartis Investigative Site

Bottrop, , Germany

Site Status

Novartis Investigative Site

Böblingen, , Germany

Site Status

Novartis Investigative Site

Brandenburg, , Germany

Site Status

Novartis Investigative Site

Bremen, , Germany

Site Status

Novartis Investigative Site

Bremerhaven, , Germany

Site Status

Novartis Investigative Site

Celle, , Germany

Site Status

Novartis Investigative Site

Chemnitz, , Germany

Site Status

Novartis Investigative Site

Chemnitz, , Germany

Site Status

Novartis Investigative Site

Cologne, , Germany

Site Status

Novartis Investigative Site

Cologne, , Germany

Site Status

Novartis Investigative Site

Cologne, , Germany

Site Status

Novartis Investigative Site

Dessau, , Germany

Site Status

Novartis Investigative Site

Dresden, , Germany

Site Status

Novartis Investigative Site

Erfurt, , Germany

Site Status

Novartis Investigative Site

Erlangen, , Germany

Site Status

Novartis Investigative Site

Essen, , Germany

Site Status

Novartis Investigative Site

Esslingen am Neckar, , Germany

Site Status

Novartis Investigative Site

Eutin, , Germany

Site Status

Novartis Investigative Site

Friedberg, , Germany

Site Status

Novartis Investigative Site

Friedrichshafen, , Germany

Site Status

Novartis Investigative Site

Gera, , Germany

Site Status

Novartis Investigative Site

Goch, , Germany

Site Status

Novartis Investigative Site

Goslar, , Germany

Site Status

Novartis Investigative Site

Göttingen, , Germany

Site Status

Novartis Investigative Site

Göttingen, , Germany

Site Status

Novartis Investigative Site

Greifswald, , Germany

Site Status

Novartis Investigative Site

Gummersbach, , Germany

Site Status

Novartis Investigative Site

Halberstadt, , Germany

Site Status

Novartis Investigative Site

Hamburg, , Germany

Site Status

Novartis Investigative Site

Hamburg, , Germany

Site Status

Novartis Investigative Site

Hamburg, , Germany

Site Status

Novartis Investigative Site

Hamelin, , Germany

Site Status

Novartis Investigative Site

Hanau, , Germany

Site Status

Novartis Investigative Site

Hanover, , Germany

Site Status

Novartis Investigative Site

Hanover, , Germany

Site Status

Novartis Investigative Site

Hanover, , Germany

Site Status

Novartis Investigative Site

Hof, , Germany

Site Status

Novartis Investigative Site

Homburg, , Germany

Site Status

Novartis Investigative Site

Kaiserslautern, , Germany

Site Status

Novartis Investigative Site

Karlsruhe, , Germany

Site Status

Novartis Investigative Site

Karlsruhe, , Germany

Site Status

Novartis Investigative Site

Kassel, , Germany

Site Status

Novartis Investigative Site

Kiel, , Germany

Site Status

Novartis Investigative Site

Koblenz, , Germany

Site Status

Novartis Investigative Site

Kulmbach, , Germany

Site Status

Novartis Investigative Site

Leipzig, , Germany

Site Status

Novartis Investigative Site

Loerrach, , Germany

Site Status

Novartis Investigative Site

Lübeck, , Germany

Site Status

Novartis Investigative Site

Mainz, , Germany

Site Status

Novartis Investigative Site

Marburg, , Germany

Site Status

Novartis Investigative Site

Marktredwitz, , Germany

Site Status

Novartis Investigative Site

Memmingen, , Germany

Site Status

Novartis Investigative Site

Minden, , Germany

Site Status

Novartis Investigative Site

Moers, , Germany

Site Status

Novartis Investigative Site

Münster, , Germany

Site Status

Novartis Investigative Site

Naunhof, , Germany

Site Status

Novartis Investigative Site

Neuruppin, , Germany

Site Status

Novartis Investigative Site

Neuss, , Germany

Site Status

Novartis Investigative Site

Neuss, , Germany

Site Status

Novartis Investigative Site

Neustadt Sachsen, , Germany

Site Status

Novartis Investigative Site

Nordhausen, , Germany

Site Status

Novartis Investigative Site

Nuremberg, , Germany

Site Status

Novartis Investigative Site

Nuremberg, , Germany

Site Status

Novartis Investigative Site

Offenbach, , Germany

Site Status

Novartis Investigative Site

Offenburg, , Germany

Site Status

Novartis Investigative Site

Oldenburg, , Germany

Site Status

Novartis Investigative Site

Osnabrück, , Germany

Site Status

Novartis Investigative Site

Passau, , Germany

Site Status

Novartis Investigative Site

Pforzheim, , Germany

Site Status

Novartis Investigative Site

Plauen Kauschwitz, , Germany

Site Status

Novartis Investigative Site

Potsdam, , Germany

Site Status

Novartis Investigative Site

Ravensburg, , Germany

Site Status

Novartis Investigative Site

Regensburg, , Germany

Site Status

Novartis Investigative Site

Rheine, , Germany

Site Status

Novartis Investigative Site

Rodgau, , Germany

Site Status

Novartis Investigative Site

Rosenheim, , Germany

Site Status

Novartis Investigative Site

Rostock, , Germany

Site Status

Novartis Investigative Site

Rostock, , Germany

Site Status

Novartis Investigative Site

Rotenburg (Wümme), , Germany

Site Status

Novartis Investigative Site

Rüsselsheim am Main, , Germany

Site Status

Novartis Investigative Site

Saarbrücken, , Germany

Site Status

Novartis Investigative Site

Saarlouis, , Germany

Site Status

Novartis Investigative Site

Salzgitter, , Germany

Site Status

Novartis Investigative Site

Schkeuditz, , Germany

Site Status

Novartis Investigative Site

Schorndorf, , Germany

Site Status

Novartis Investigative Site

Schwäbisch Hall, , Germany

Site Status

Novartis Investigative Site

Schweinfurt, , Germany

Site Status

Novartis Investigative Site

Soest, , Germany

Site Status

Novartis Investigative Site

Stade, , Germany

Site Status

Novartis Investigative Site

Stendal, , Germany

Site Status

Novartis Investigative Site

Stolberg, , Germany

Site Status

Novartis Investigative Site

Stuttgart, , Germany

Site Status

Novartis Investigative Site

Stuttgart, , Germany

Site Status

Novartis Investigative Site

Suhl, , Germany

Site Status

Novartis Investigative Site

Torgau, , Germany

Site Status

Novartis Investigative Site

Trier, , Germany

Site Status

Novartis Investigative Site

Tübingen, , Germany

Site Status

Novartis Investigative Site

Ulm, , Germany

Site Status

Novartis Investigative Site

Ulm, , Germany

Site Status

Novartis Investigative Site

Vechta, , Germany

Site Status

Novartis Investigative Site

Völklingen, , Germany

Site Status

Novartis Investigative Site

Weiden, , Germany

Site Status

Novartis Investigative Site

Weinheim, , Germany

Site Status

Novartis Investigative Site

Wetzlar, , Germany

Site Status

Novartis Investigative Site

Wiesbaden, , Germany

Site Status

Novartis Investigative Site

Wilhelmshaven, , Germany

Site Status

Novartis Investigative Site

Wolfsburg, , Germany

Site Status

Novartis Investigative Site

Worms, , Germany

Site Status

Novartis Investigative Site

Würselen, , Germany

Site Status

Novartis Investigative Site

Würzburg, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Decker T, Brucker C, Engel A, Fasching PA, Gohler T, Jackisch C, Janssen J, Kohler A, Ludtke-Heckenkamp K, Luftner D, Marme F, van Mackelenbergh M, Rautenberg B, Schmidt M, Weide R, Wimberger P, Kisseleff E, Pfister C, Roos C, Wilhelm N, Wockel A. Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study. ESMO Open. 2025 Jun;10(6):105105. doi: 10.1016/j.esmoop.2025.105105. Epub 2025 May 16.

Reference Type RESULT
PMID: 40381382 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLEE011ADE03

Identifier Type: -

Identifier Source: org_study_id